External validation of a genomic signature for oligometastatic non-small cell lung cancer.
In this independent dataset, our genomic signature predicted oligometastatic disease state and showed a trend towards prediction of oligoprogression. With further study, our findings may suggest a biomarker with future potential to direct local therapies in oligometastatic NSCLC patients.
Authors
- Christopher T. Whitlow (ORCID: https://orcid.org/0000-0003-2392-8293)
- C.M. Lanier (ORCID: https://orcid.org/0000-0003-0127-9253)
- Ralph B. D’Agostino (ORCID: https://orcid.org/0000-0002-3550-8395)
- Fei Xing (ORCID: https://orcid.org/0000-0001-6350-0764)
- Jing Su (ORCID: https://orcid.org/0000-0003-4917-6173)
- Michael Farris (ORCID: https://orcid.org/0000-0003-2948-227X)
- Wencheng Li (ORCID: https://orcid.org/0000-0002-4176-8249)
- Thomas Lycan (ORCID: https://orcid.org/0000-0001-9475-1558)
- Jimmy Ruiz (ORCID: https://orcid.org/0000-0002-7242-3315)
- W. Jeffrey Petty (ORCID: https://orcid.org/0000-0002-1553-1838)
- Michael D. Chan (ORCID: https://orcid.org/0000-0002-5278-6709)
- Christina K. Cramer (ORCID: https://orcid.org/0000-0001-7618-3921)
- Margaret Smith (ORCID: https://orcid.org/0000-0002-3523-7150)
- Mohammed Abdulhaleem (ORCID: https://orcid.org/0000-0002-4429-2178)
- Ariel R. Choi (ORCID: https://orcid.org/0000-0002-0542-6436)
- Sarah Glynn
- Yuezhu Wang (ORCID: https://orcid.org/0009-0004-9175-2589)
Institutions
- West Virginia University (US)
- West Virginia University Hospitals (US)
- Indiana University School of Medicine
- Wake Forest University (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- PubMed
- Published
- 2025-01-01
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00